NO20054208L - Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter - Google Patents

Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter

Info

Publication number
NO20054208L
NO20054208L NO20054208A NO20054208A NO20054208L NO 20054208 L NO20054208 L NO 20054208L NO 20054208 A NO20054208 A NO 20054208A NO 20054208 A NO20054208 A NO 20054208A NO 20054208 L NO20054208 L NO 20054208L
Authority
NO
Norway
Prior art keywords
pyrimidine
preparation
medicaments
nitrogen
methods
Prior art date
Application number
NO20054208A
Other languages
English (en)
Norwegian (no)
Inventor
Pavel Safar
Gregory Harold Merriman
Kenneth J Bordeau
Matthias Gossel
Thomas Klabunde
Stefanie Flohr
Petra Stahl
James Spoonamore
Martin Smrcina
Joseph T Klein
Brian Whiteley
Carolina Lanter
Zhaoxia Yang
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10305885A external-priority patent/DE10305885A1/de
Priority claimed from DE10349671A external-priority patent/DE10349671A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20054208L publication Critical patent/NO20054208L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20054208A 2003-02-13 2005-09-09 Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter NO20054208L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10305885A DE10305885A1 (de) 2003-02-13 2003-02-13 Substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10349671A DE10349671A1 (de) 2003-10-24 2003-10-24 Stickstoff substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2004/000770 WO2004072077A1 (fr) 2003-02-13 2004-01-29 Derives de hexahydro-pyrazino[1,2-a]pyrimidine-4,7-diones a substitution azote, procedes de fabrication et utilisation en tant qu'agents pharmaceutiques

Publications (1)

Publication Number Publication Date
NO20054208L true NO20054208L (no) 2005-09-09

Family

ID=32870333

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054208A NO20054208L (no) 2003-02-13 2005-09-09 Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter

Country Status (20)

Country Link
EP (1) EP1597259B1 (fr)
JP (1) JP2006517551A (fr)
KR (1) KR20050100686A (fr)
AR (1) AR043154A1 (fr)
AT (1) ATE393769T1 (fr)
AU (1) AU2004212043A1 (fr)
BR (1) BRPI0407387A (fr)
CA (1) CA2514791A1 (fr)
CO (1) CO5690596A2 (fr)
DE (1) DE502004007000D1 (fr)
HR (1) HRP20050711A2 (fr)
MA (1) MA27734A1 (fr)
MX (1) MXPA05008288A (fr)
NO (1) NO20054208L (fr)
PE (1) PE20040949A1 (fr)
PL (1) PL377660A1 (fr)
RS (1) RS20050572A (fr)
RU (1) RU2005128499A (fr)
TW (1) TW200510417A (fr)
WO (1) WO2004072077A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
CA2515735A1 (fr) * 2003-02-13 2004-08-26 Aventis Pharma Deutschland Gmbh Derives de hexahydro-pyrazino(1,2-a)pyrimidine-4,7-diones substitues, procedes de fabrication et utilisation en tant qu'agents pharmaceutiques
DE102004042441A1 (de) * 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2308840A1 (fr) 2005-06-30 2011-04-13 Prosidion Limited Agonistes de GPCR
JP5102985B2 (ja) * 2006-07-18 2012-12-19 東ソ−・エフテック株式会社 含フッ素２級アミン化合物の製造方法
WO2008017381A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
EP2114933B1 (fr) 2007-01-04 2011-09-07 Prosidion Ltd Agonistes du gpcr de pipéridine
EP2114936A1 (fr) 2007-01-04 2009-11-11 Prosidion Limited Agonistes de gpcr pipéridiniques
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
JP5204438B2 (ja) * 2007-07-31 2013-06-05 東ソ−・エフテック株式会社 含フッ素アミン化合物の製造方法
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
JP5545573B2 (ja) 2008-10-14 2014-07-09 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ アルファへリックスミメティック及び関連の方法
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
JP5768239B2 (ja) 2009-05-07 2015-08-26 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ アルファへリックスミメティック及び関連の方法
CA2771278A1 (fr) 2009-08-26 2011-03-03 Sanofi Nouveaux hydrates de fluoroglycoside heteroaromatiques cristallins, substances pharmaceutiques comprenant ces composes et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
CN109640970B (zh) 2016-06-23 2023-05-23 马里兰大学巴尔的摩分校 选择性p38α特异性MAPK抑制剂
AU2019392904B9 (en) 2018-12-07 2022-12-22 University Of Maryland, Baltimore Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
CN116406355A (zh) 2020-05-18 2023-07-07 Gen1E生命科学公司 P38α促分裂原活化蛋白激酶抑制剂
IL302235A (en) 2020-10-29 2023-06-01 Gen1E Lifesciences Inc 5-(dimethylamino)-N-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide dihydrochloride dihydrate crystalline
JP2024516512A (ja) 2021-03-23 2024-04-16 ジーニー ライフサイエンシズ インコーポレイテッド 置換ナフチルｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO1998058947A1 (fr) * 1997-06-25 1998-12-30 Pfizer Inc. Derives dipeptides secretagogues de l'hormone de croissance
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
CA2515735A1 (fr) * 2003-02-13 2004-08-26 Aventis Pharma Deutschland Gmbh Derives de hexahydro-pyrazino(1,2-a)pyrimidine-4,7-diones substitues, procedes de fabrication et utilisation en tant qu'agents pharmaceutiques

Also Published As

Publication number Publication date
WO2004072077A1 (fr) 2004-08-26
KR20050100686A (ko) 2005-10-19
MA27734A1 (fr) 2006-02-01
BRPI0407387A (pt) 2006-02-07
DE502004007000D1 (de) 2008-06-12
RS20050572A (en) 2007-09-21
PE20040949A1 (es) 2005-01-12
CO5690596A2 (es) 2006-10-31
EP1597259B1 (fr) 2008-04-30
HRP20050711A2 (en) 2006-09-30
AR043154A1 (es) 2005-07-20
EP1597259A1 (fr) 2005-11-23
PL377660A1 (pl) 2006-02-06
ATE393769T1 (de) 2008-05-15
TW200510417A (en) 2005-03-16
CA2514791A1 (fr) 2004-08-26
MXPA05008288A (es) 2006-03-21
AU2004212043A1 (en) 2004-08-26
JP2006517551A (ja) 2006-07-27
RU2005128499A (ru) 2006-01-27

Similar Documents

Publication Publication Date Title
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
NO20054085L (no) Substituerte heksahydropyrazino [1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
TW200510297A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
TW200606162A (en) Pyrazolopyridine derivatives
NO20056032L (no) Nye pyridopyraziner og anvendelse derav som kinasemodulatorer
GEP20094720B (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
TW200504062A (en) Novel pyridopyrazines and the use thereof as kinase inhibitors
NO20053809L (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
ATE433450T1 (de) Substituierte 1,4,8-triazaspiro 4.5 decan-2-on- verbindungen
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
CY1109460T1 (el) Υποκατεστημενες ενωσεις 5,6,7,8-τετραϋδρο-ιμιδαζο[1,2-α]-πυριδιν-2-υλαμινης και η χρησιμοποιηση τους για την παρασκευη φαρμακων
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
WO2006071564A3 (fr) Sels amines de 1,2,3-triazoles utilises comme promedicaments comprenant des agents antiviraux
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
NO20063618L (no) Diarylmetylpiperidinderivater, fremstilling og anvendelse derav
HK1056362A1 (en) Triazolo Ä4,5-dÜ pyrimidine derivatives as anti-thrombotic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application